Mode
Text Size
Log in / Sign up
N/A N=89 Randomized Single-blind Treatment

Skills Based Counseling for Adherence and Depression in HIV+ Methadone Patients - 1

Adherence · Depression · Heroin Dependence · Methadone · Motivational Interviewing

Enrolled (actual)
89
Serious AEs
0.0%
Results posted
Jul 2012
Primary outcome: Primary: Percent Medication Adherence at 3-month Follow-up Assessment — 79.02; 73.66 percent (doses taken/doses prescribed) — p=<.05

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
CBT-AD (Behavioral); ETAU (Behavioral)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Massachusetts General Hospital
Primary completion
Jul 2009

Outcome Measures

OutcomeResultp-value
PRIMARY
Percent Medication Adherence at 3-month Follow-up Assessment
79.02; 73.66 <.05 sig
PRIMARY
Percent Medication Adherence at 12-month Follow-up Assessment
64.49; 61.11
SECONDARY
Clinician-assessed Depression Rating at 3 Month Follow-up Assessment
17.02; 22.7 <.05 sig
SECONDARY
HIV Viral Load at 12-month Follow-up Assessment
2.203; 2.177
SECONDARY
CD4+ Lymphocyte Count at 12-month Follow-up Assessment.
452.94; 502.33 <.05 sig
SECONDARY
Clinician-assessed Depression at 12-month Follow-up Assessment
15.28; 20.00
SECONDARY
HIV Viral Load at 3-month Follow-up Assessment
2.349; 2.044
SECONDARY
CD4+ Lymphocyte Count at 3-month Follow-up Assessment.
380.97; 539.29

Summary

Patients with HIV, depression, and opioid-dependence are at high risk for poor health outcomes. This is a two-arm randomized controlled trial of cognitive-behavioral therapy for depression and HIV medication adherence in patients with opioid dependence who are receiving methadone maintenance treatment. The project is based on our pilot work with close attention to NIDA guidelines for a staged approach to treatment development and testing (Rounsaville et al., 2001). Depression is highly comorbid with both HIV infection and with opioid dependence. Depression and substance abuse are both associated with poor adherence to antiretroviral medications. Patients with HIV, depression, and opioid dependence are at high risk for poor health outcomes. Cognitive-behavioral therapy is the most widely studied and efficacious psychosocial intervention for depression; and research by the PI and others has shown that cognitive-behavioral interventions have been successful in promoting adherence to HIV medications.

Eligibility Criteria

Inclusion Criteria

  • HIV seropositive
  • Currently enrolled in methadone maintenance treatment for at least one month
  • Current major or subsyndromal depression (subsyndromal depression is defined by major depression that does not meet full diagnostic criteria but with a clinical global impression of severity (CGI-S) of 2 (mildly ill))
  • Is prescribed antiretroviral therapy for HIV and therefore under the care of a primary care provider.
  • Between the ages of 18 and 65.

Exclusion Criteria

  • Active untreated, unstable, major mental illness (i.e., untreated psychosis or mania), or other Axis I psychiatric disorders (other than depression) that would interfere with the ability to participate (i.e. CGI-S >6)
  • Unable or unwilling to provide informed consent.
  • Currently in cognitive behavioral therapy for depression.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00218634). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search